drugset / Trial / NCT04330079

Effects of dapaglifloziN Therapy on Myocardial Perfusion Reserve in Prediabetic Patients With Stable coronarY Artery Disease

NCT04330079 ↗

Phase 4 Terminated 2 enrolled CHEOL WHAN LEE, M.D., Ph.D
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the effects of dapagliflozin therapy on myocardial perfusion reserve (MPR) using dynamic SPECT examination in prediabetic patients with stable CAD. Dapagliflozin therapy versus lifestyle modification improves myocardial perfusion reserve in prediabetic patients with stable CAD.

Timeline

Start
2020-05-21
Primary completion
2021-04-08
Completion
2021-04-08

Outcome

Outcome not reported

Stopped (Enrollment): “Slow enrollment. (Difficulty in selecting subjects)”

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule 10 mg —